New vaccine combo takes on tough lung cancer in early trial
NCT ID NCT07614646
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new cancer vaccine (EVM14) combined with an immunotherapy drug (ivonescimab) in 13 people with advanced squamous non-small cell lung cancer that has not been treated before. The main goals are to check safety and find the right dose, while also looking at whether the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EVM14 (cancer vaccine) and ivonescimab (immunotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for advanced squamous non-small cell lung cancer, potentially improving tumor control.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The vaccine may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••